435 related articles for article (PubMed ID: 33611603)
21. The Role of Immunotherapy in the Management of Soft Tissue Sarcomas: Current Landscape and Future Outlook.
Banks LB; D'Angelo SP
J Natl Compr Canc Netw; 2022 Jul; 20(7):834-844. PubMed ID: 35830892
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapeutic approaches to sarcoma.
Burgess M; Tawbi H
Curr Treat Options Oncol; 2015 Jun; 16(6):26. PubMed ID: 25975445
[TBL] [Abstract][Full Text] [Related]
23. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
24. The current landscape of early drug development for patients with sarcoma in the immunotherapy era.
Sebio A; Wilky BA; Keedy VL; Jones RL
Future Oncol; 2018 May; 14(12):1197-1211. PubMed ID: 29699407
[TBL] [Abstract][Full Text] [Related]
25. Emerging Trends in Immunotherapy for Adult Sarcomas.
Husain M; Chen L; Liebner D; Beane J; Rubinstein M; Pollock R; Verschraegen C; Tinoco G
Oncologist; 2023 May; 28(5):e233-e241. PubMed ID: 36905579
[TBL] [Abstract][Full Text] [Related]
26. Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines.
Nowicki TS; Anderson JL; Federman N
Pediatr Res; 2016 Mar; 79(3):371-7. PubMed ID: 26595537
[TBL] [Abstract][Full Text] [Related]
27. From vision to reality: deploying the immune system for treatment of sarcoma.
Wilky BA; Goldberg JM
Discov Med; 2017 Jan; 23(124):61-74. PubMed ID: 28245428
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy for Bone and Soft Tissue Sarcomas.
Uehara T; Fujiwara T; Takeda K; Kunisada T; Ozaki T; Udono H
Biomed Res Int; 2015; 2015():820813. PubMed ID: 26167500
[TBL] [Abstract][Full Text] [Related]
29. Clinical and immunological characteristics of sarcomas patients with clonogenic tumors.
Avdonkina NA; Danilova AB; Nekhaeva TL; Prosekina EA; Emelyanova NV; Novik AV; Girdyuk DV; Gafton GI; Baldueva IA
Immunobiology; 2021 Jul; 226(4):152094. PubMed ID: 34052775
[TBL] [Abstract][Full Text] [Related]
30. Undifferentiated and Dedifferentiated Metastatic Melanomas Masquerading as Soft Tissue Sarcomas: Mutational Signature Analysis and Immunotherapy Response.
Kasago IS; Chatila WK; Lezcano CM; Febres-Aldana CA; Schultz N; Vanderbilt C; Dogan S; Bartlett EK; D'Angelo SP; Tap WD; Singer S; Ladanyi M; Shoushtari AN; Busam KJ; Hameed M
Mod Pathol; 2023 Aug; 36(8):100165. PubMed ID: 36990277
[TBL] [Abstract][Full Text] [Related]
31. Sarcomas-A barren immunological wasteland or field of opportunity for immunotherapy?
Atherton MJ; Lenz JA; Mason NJ
Vet Comp Oncol; 2020 Dec; 18(4):447-470. PubMed ID: 32246517
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy in Sarcoma: Current Data and Promising Strategies.
Wood GE; Meyer C; Petitprez F; D'Angelo SP
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432234. PubMed ID: 38781557
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy and Biomarkers in Sarcoma.
Dajsakdipon T; Siripoon T; Ngamphaiboon N; Ativitavas T; Dejthevaporn T
Curr Treat Options Oncol; 2022 Mar; 23(3):415-438. PubMed ID: 35262852
[TBL] [Abstract][Full Text] [Related]
34. Soft tissue sarcoma as a model disease to examine cancer immunotherapy.
Maki RG
Curr Opin Oncol; 2001 Jul; 13(4):270-4. PubMed ID: 11429485
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy in soft-tissue sarcoma.
Ayodele O; Razak ARA
Curr Oncol; 2020 Feb; 27(Suppl 1):17-23. PubMed ID: 32174754
[TBL] [Abstract][Full Text] [Related]
36. Immune checkpoint inhibitors in sarcomas: a systematic review.
Anastasiou M; Kyriazoglou A; Kotsantis I; Economopoulou P; Kyrkasiadou M; Giannopoulou A; Kosmidou A; Smerdi D; Moutafi M; Gavrielatou N; Psyrri A
Immunooncol Technol; 2023 Dec; 20():100407. PubMed ID: 38192615
[TBL] [Abstract][Full Text] [Related]
37. Role of Immunotherapy in Sarcomas.
Dalal S; Shan KS; Thaw Dar NN; Hussein A; Ergle A
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279265
[TBL] [Abstract][Full Text] [Related]
38. B cells are associated with survival and immunotherapy response in sarcoma.
Petitprez F; de Reyniès A; Keung EZ; Chen TW; Sun CM; Calderaro J; Jeng YM; Hsiao LP; Lacroix L; Bougoüin A; Moreira M; Lacroix G; Natario I; Adam J; Lucchesi C; Laizet YH; Toulmonde M; Burgess MA; Bolejack V; Reinke D; Wani KM; Wang WL; Lazar AJ; Roland CL; Wargo JA; Italiano A; Sautès-Fridman C; Tawbi HA; Fridman WH
Nature; 2020 Jan; 577(7791):556-560. PubMed ID: 31942077
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy of sarcomas.
Goldberg JM
Curr Opin Oncol; 2013 Jul; 25(4):390-7. PubMed ID: 23736878
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade.
Mougel A; Terme M; Tanchot C
Front Immunol; 2019; 10():467. PubMed ID: 30923527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]